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Background: Learning by conditioning is a key ability of animals and humans for acquiring novel 
behavior necessary for survival in a changing environment. Aberrant conditioning has been considered 
a crucial factor in the etiology and maintenance of panic disorder with agoraphobia (PD/A). Cognitive-
behavioral therapy (CBT) is an effective treatment for PD/A. However, the neural mechanisms 
underlying the effects of CBT on conditioning processes in PD/A are unknown.  
 
Methods: In a randomized, controlled, multicenter clinical trial in medication-free patients with PD/A 
who were treated with 12 sessions of manualized CBT, functional magnetic resonance imaging (fMRI) 
was used during fear conditioning before and after CBT. Quality-controlled fMRI data from 42 
patients and 42 healthy subjects were obtained.  
 
Results: After CBT, patients compared to control subjects revealed reduced activation for the 
conditioned response (CS+ > CS–) in the left inferior frontal gyrus (IFG). This activation reduction 
was correlated with reduction in agoraphobic symptoms from t1 to t2. Patients compared to control 
subjects also demonstrated increased connectivity between the IFG and regions of the “fear network” 
(amygdalae, insulae, anterior cingulate cortex) across time.  
 
Conclusions: This study demonstrates the link between cerebral correlates of cognitive (IFG) and 
emotional (“fear network”) processing during symptom improvement across time in PD/A. Further 
research along this line has promising potential to support the development and further optimization of 
targeted treatments.  
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Panic disorder is a debilitating anxiety disorder with a lifetime prevalence of approximately 
3% to 5%. It is characterized by intermittent and sudden extreme anxiety, vegetative 
symptoms, and concerns about the implications of the attacks. Agoraphobia, the anticipatory 
anxiety or avoidance of situations in which escape or help may not be available in case of 
panic symptoms, is a frequent consequence (1). An interaction of biological vulnerability 
(2,3), learning history and acute stress underlies the etiology of panic disorder with 
agoraphobia (PD/A) (4–6). Cognitive-behavioral therapy (CBT) and/or selective serotonin 
reuptake inhibitors are effective first-line treatments for PD/A (4,7).  
 
The onset and continuation of some anxiety disorders, particularly panic disorder, has been 
linked to aberrant learning (conditioning) processes (5,8–10). Fear conditioning is a form of 
associative learning in which contingencies are established by pairing aversive stimuli 
(unconditioned stimulus [US]) with previously neutral stimuli (conditioned stimulus [CS]). 
Brain imaging studies have related fear conditioning to a neural network including the 
amygdalae (11–14), insulae (14), anterior cingulate cortex (ACC) (14), and medial frontal 
gyrus (“fear network”) (13,15). This network has substantial overlap with fear circuitry 
structures that have been reported to show aberrant activation in different anxiety disorders 
(16,17). Studies with functional magnetic resonance imaging (fMRI) in patients with panic 
disorder have implicated the amygdala, anterior insula, ACC, and medial frontal gyrus in the 
disorder (15), supporting the role of the “fear network” in its pathophysiology (13,15). 
However, with regard to fear conditioning in PD/A, to our knowledge only one imaging study 
has been conducted so far. Increased activity with regard to the CS– had been observed in the 
amygdala, subgenual cingulate, and midbrain structures using an instructed fear paradigm 
(18).  
 
Whereas the neural correlates of treatment effects on patients with specific phobia (19,20) or 
obsessive-compulsive disorder (21) have been investigated in a number of studies (see Porto 
et al. [22] and Linden [23] for reviews), the neural mechanisms underlying PD/A and its 
potential changes through CBT remain largely unknown. To date, only two positron emission 
tomography (PET) studies have examined the modulation of brain physiology with CBT in 
PD using a resting state paradigm (24,25). In the first study, the CBT group (6 patients) 
showed decreases in regions of the right inferior temporal and superior and inferior frontal 
gyrus (IFG), and increases were detected in the left IFG, middle temporal gyrus, and insula 
(25). In the other PET study, 11 patients with PD who improved after CBT were investigated 
(24). Here, glucose utilization increased in the bilateral medial prefrontal cortices and 
decreased in the right hippocampus, left ACC, left cerebellum, and pons. Thus, these studies 
provide first support for CBT modulating brain activation in PD, most consistently in frontal 
brain regions. However, it is unknown how these changes in brain activation during rest are 
related to processes associated with panic disorder, such as conditioning.  
 
Particular regions within the frontal cortex might be relevant for the psychopathology 
(18,26,27) and its treatment of PD/A (15). Medial and orbitofrontal brain regions are 
associated with emotion regulation/reduction and provide direct connections to the amygdala. 
The lateral prefrontal cortex and specifically the left inferior frontal gyrus/sulcus (Brodmann 
area 44), which is indirectly linked to the amygdala (28,29), is implicated in voluntary 
increase of emotions and anticipation of panic attacks (30,31). Thus, cognitions are able to 
increase or decrease emotional responses efficiently (32). Correspondingly, positive, negative, 
or bidirectional associations between frontal activity and activation of the fear network have 
been demonstrated (28,33–37). However, it is unknown whether patients with PD/A suffer 
either from a lack of cognitive control over normal emotional responses or from negative 
cognitions which trigger or amplify extreme emotional reactions.  
 
In this fMRI study, we investigated the influence of CBT on the neural correlates of fear 
conditioning in PD/A. We hypothesized that CBT will modify activation during fear 
acquisition in regions of the prefrontal cortex and the “fear network”. Whereas the applied 
fear conditioning paradigm should probe automatic fear learning mechanisms predominantly 
in the “fear network” (amygdalae, hippocampi, anterior insulae, ACC), we expected that CBT 
will primarily act on negative cognitions triggered by conditioned stimuli in PD/A patients. 
The neural correlates of negative cognitions (e.g., selective attention to threat) are assumed to 
be related to the left lateral frontal cortex. Whereas reduction of activation in “fear network” 
areas as a result of symptom improvement are likely, there were two possible result patterns 
for regions of the prefrontal lobe: increased prefrontal activation after CBT would indicate 
compensation or reappraisal processes, whereas decreased activity would rather speak for a 
reduction of negative cognitions. Consequently two result patterns can be assumed for the 
connectivity between frontal regions (“cognitive processes”) activated during fear 
conditioning and the “fear network” (“emotional processes”) in PD/A. A negative 
connectivity would indicate inhibition or reappraisal processes, whereas a positive correlation 
would rather suggest that negative cognitions trigger emotional responses.  
 
Methods and Materials  
 
Participants  
 
The present study was part of the national research network PANIC-NET (7,38,39) 
encompassing a randomized controlled clinical trial on CBT and experimental add-on studies 
on fear circuit mechanisms in PD/A. Eight German centers participated in the clinical trial 
(Aachen, Berlin-Adlershof, Berlin-Charité, Bremen, Dresden, Greifswald, Münster, 
Würzburg) treating 369 patients who met DSM-IV criteria for PD/A. Four of these centers 
(Aachen, Berlin- Charité, Dresden, Münster) also participated in the fMRI study reported 
here.  
 
In the context of the fMRI part of the clinical multicenter study (38), quality controlled fMRI 
data (for details of the procedure, see Supplement 1) were collected 8 weeks apart from 42 
unmedicated patients with PD/A before and after CBT as well as 42 healthy control subjects 
matched for age, gender, and handedness (40) (see Table 1 and Figure S1 in Supplement 1). 
For a description of the applied clinical assessments as well as inclusion and exclusion 
criteria, see Supplement 1 and (7,38). After a complete description of the study protocol, 
written informed consent was obtained from every participant and the protocol was approved 
by the local ethics committees in each fMRI center according to the Declaration of Helsinki.  
 
Procedure: Treatment and Clinical Assessment  
 
CBT was administered in 12 twice-weekly sessions based on a highly standardized and 
controlled treatment protocol (see Supplement 1 Information and Gloster et al. [7,38]). PD/A 
patients were randomly assigned to two versions of CBT, which differed only in therapist-
guided or non-therapist-guided exposure sessions (sessions 6–8 and 9–11). Because both 
groups received a comparable treatment and demonstrated significant symptom reduction 
after CBT (7), groups were collapsed in the current study.  
 
In addition to those assessments of the clinical trial, cognitive abilities were assessed using 
Trail Making Test A and B (TMT-A/B) and digit span.  
 
Paradigm-specific behavioral data were collected before fMRI data acquisition for the US 
(aversiveness rating at t1; from 0 not aversive to 10 very aversive) and during fMRI data 
acquisition for both conditioned stimuli (CS+ and CS–) at three time points: after the 
familiarization, after the acquisition and after the extinction phase using the Self-Assessment 
Manikin (SAM) (41), with a 5-point Likert scale (1 = very unpleasant to 5 = very pleasant and 
1 = not arousing to 5 = very arousing). Behavioral data of the acquisition phase are given in 
the result section. The complete rating data were provided in Supplement 1 (Table S2).  
 
fMRI  
 
Parallel versions of a previously validated differential conditioning paradigm were applied 
during MRI data acquisition (Figure 1) (41) before and after CBT. All patients and control 
subjects were measured at the same fMRI scanner at t1 and t2. In the fMRI analysis 
(discussed below), we compared the difference between CS+ and CS– across t1 and t2 to 
examine the therapy-related changes of the conditioning processes.  
 
fMRI Data Acquisition and Preprocessing  
 
fMRI brain images were acquired using 3T Philips Achieva scanners (Philips Medical 
Systems, Best, The Netherlands) in Münster and Aachen, a 3T Siemens Trio scanner 
(Siemens AG, Erlangen, Germany) in Dresden, and a 3T General Electric Healthcare scanner 
(General Electric Healthcare, Milwaukee, Wisconsin) in Berlin.Atotal of 505 transaxial 
functional images (echo-planar images, 64 × 64, 30 slices interleaved, field of view = 230, 
voxel size = 3.6×3.6×3.8 mm, echo time = 30 msec, repetition time = 2 sec) that covered the 
whole brain and were positioned parallel to the intercomissural line (anterior commissure–
posterior commissure) were recorded.  
 
Magnetic resonance images were analyzed using Statistical Parametric Mapping (SPM5; 
www.fil.ion.ucl.ac.uk) implemented in MATLAB 7.1 (Mathworks, Sherborn, Massachusetts). 
The first five volumes of every functional run were discarded to minimize t1 saturation 
effects. For data preprocessing, standard slice-timing (middle slice), realignment and 
normalizing (2×2×2 mm3) functions of SPM5 were applied. To account for differences in 
intrinsic smoothness between scanners, an iterative smoothness equalization (42) procedure 
was performed for all data sets using an target smoothness of 12-mm full width at half 
maximum Gaussian isotropic kernel. Thus, data from all centers have been iteratively 
smoothed until a smoothness of 12-mm full width at half maximum was reached, independent 
of scanner-specific intrinsic smoothness of the data. Finally, the quality (43,44) of the 
acquired data was carefully checked to avoid systematic differences between the patient and 
control groups (Supplement 1).  
 
Single Subject fMRI Analyses  
 
At the single-subject level, the realignment parameters of each participant were included as 
regressors into the model to account for movement artifacts of the participants. The blood 
oxygen level-dependent (BOLD) response for each event type (CS+paired, CS+unpaired, CS–
, US) and each phase (F1, F2, A1, A2, E1, E2; see Figure 1) was modeled by the canonical 
hemodynamic response function employed by SPM5 within the framework of the general 
linear model to analyse brain activation differences related to the onset of the different 
stimuli. Each phase was separated into an early and a late part to account for temporal aspects 
and habituation (45), resulting in 16 regressors (familiarization: early CS+, late CS+; early 
CS–, late CS–; US; acquisition: early CS–, late CS–, CS presented with the US (CS+paired); 
US; early CS+ without US (CS+unpaired), late CS+unpaired; extinction: early CS–, late CS–; 
early CS+, late CS+; behavioral assessment).  
 
A high-pass filter (128-sec cutoff period) was applied to remove low frequency fluctuations in 
the BOLD signal. Parameter estimates (β) and t statistic images were calculated for each 
subject.  
 
Connectivity Analyses  
 
For the connectivity analyses, eigenvectors adjusted for the effect of movement parameters 
were extracted from the entire IFG cluster (identified in the group analysis) on a single-
subject level across the whole experiment (500 scans). The individual eigenvectors were used 
as regressors in new single-subject analyses that additionally included the six movement 
regressors. We obtained individual activation maps reflecting the correlation of each voxel 
time course with the time course of the left IFG as outcomes for each time point and group. 
These images were used in the group analyses (flexible factorial analyses) focusing on the 
main effects and interactions of group and time.  
 
Group Analyses  
 
Random effects group analyses were performed by entering contrast images into flexible 
factorial analyses as implemented in SPM5, in which subjects are treated as random variables. 
The fMRI center was introduced as a covariate to account for scanner differences. Further 
covariates of no interest included education level, for which we found group differences, and 
the depression score (Beck Depression Inventory-II) that might be confounded with panic-
specific treatment effects in the current sample. Other variables, such as age, gender, and 
aversiveness rating, had been checked. However, they did not significantly change our results.  
 
A Monte Carlo simulation of the brain volume of the current study was conducted to establish 
an appropriate voxel contiguity threshold (46). The calculation of the cluster size to correct 
for multiple comparisons is based on algorithms that accounted for the difference of original 
and normalized cluster sizes as well as smoothing kernel and total volume of data acquisition 
(47,48). Assuming an individual voxel type I error of p<.005, a cluster extent of 142 
contiguous resampled voxels (1136 mm3) was indicated as sufficient to correct for multiple 
voxel comparisons at p<.05. Thus, voxels with a significance level of p<.005 uncorrected 
belonging to clusters with at least 142 voxels (1136 mm3) were reported for all analyses.  
 
For the left IFG cluster, percent signal change was extracted separately for each stimulus 
class. Percent signal change was calculated by applying the MarsBaR 
(http://marsbar.sourceforge.net) toolbox for SPM.  
 
Results  
 
Clinical Improvement  
 
Results of the clinical trial in a much larger patient sample, which demonstrate the efficiency 
of the CBT treatment, are reported elsewhere in detail (7). In the smaller subgroup of patients 
who participated in our fMRI study, we obtained a significant reduction of symptoms after 
therapy (e.g., Clinical Global Impressions Scale; Hamilton Anxiety Scale; Panic and 
Agoraphobia Scale; Anxiety Sensitivity Index; 7-day version of the Mobility Inventory; Table 
1), which supports the efficiency of the CBT treatment in this study.  
 
Behavioral Results of the Conditioning Experiment  
 
The rating of valence and arousal with regard to the stimuli (CS+ and CS–, respectively) that 
were acquired after the acquisition phase (41) (Figure 1) support the validity of our paradigm 
in demonstrating a main effect of condition for valence [CS– > CS+; F(1,80) = 12.481, p = 
.001; partial eta squared = .135] and arousal [CS+ > CS–; F(1,80) = 11.767, p = .001; partial 
eta squared = .128] in an analysis of variance. Thus, the conditioned stimulus (CS+) was 
evaluated as less positive (low valence) and more arousing (high arousal) than the control 
stimulus (CS–). The significant effect of group indicates general lower ratings of valence [P < 
C; F(1,80) = 7.677, p = .007; partial-eta squared = .088) and higher ratings of arousal for 
patients in contrast to the control group [P > C; F(1,80) = 9.060,p = .003; partial eta squared = 
.102].The effect of time point was significant for valance ratings only [valence: t1 < t2; 
F(1,80) = 4.495, p = .037; partial eta squared = .053; arousal: F(1,80) = 2.383, p = .127; 
partial eta squared = .029].However, the interaction of group and time point; group and 
condition; or group, time point, and condition for both valence and arousal did not reach 
significance (all ps > .10).  
 
fMRI Results  
 
For the effect of CBT on the conditioned response (CS+unpaired > CS–) in the patient versus 
the control group (interaction group × time),wefound activation of the left IFG extending into 
the anterior insula (Figure 2). Importantly, this effect was already present in the early phase of 
fear acquisition (A1; Figure 1) (45). Post hoc analyses indicate that this interaction effect was 
driven by a significant activation reduction (t1 > t2) in the patient group (Figure S2 in 
Supplement 1). This reduction in BOLD signal from t1 to t2 was correlated with reduction in 
agoraphobic symptoms from t1 to t2 (Mobility Inventory (38), a main outcome measure of the 
clinical trial (7); Spearman’s rho: r = .353; p < .05 corrected for multiple comparisons). 
Correlations with the other outcome measures (Hamilton Anxiety Scale, Clinical Global 
Impressions Scale, or number of panic attacks) were not significant (Table S3 in Supplement 
1), indicating a specific relation to agoraphobic avoidance. The same fMRI analyses 
performed for the other experimental phases (F1, F2, A2, E1, E2; Figure 1) and the opposite 
contrasts (CS+ < CS–) did not show any significant activation (except for a nonpredicted 
single cluster in the parietal lobe for C > P in A2). When analyzing the two groups (P and C) 
separately across time (t1 > t2), we found a reduced conditioned response (CS+ > CS–) at t2 
in the left amygdala, insula, the bilateral basal ganglia, and the ACC (“fear network”) (13) for 
the patient but not the control group (Table 2). For further main effects as well as the effects 
of the US, see Figure S3 and S4 in Supplement 1.  
 
Connectivity Analyses  
 
We found a significant main effect for group (P/C), indicating a higher functional 
connectivity in patients (P > C) between the left IFG and the bilateral amygdalae, the 
hippocampi, the ACC, and the medial and lateral PFCs (Figure 3). There was no significant 
interaction effect across group and time (t1/t2).  
 
To explore the clinical relevance of the left IFG connectivity analyses, we included the main 
outcome measures from the clinical trial (7) predefined before the start of the study (Hamilton 
Anxiety Scale, Clinical Global Impressions Scale, number of panic attacks [PA], and the 
Mobility Inventory scores) as covariate of interest in the analyses. First, we explored the 
effect of the covariates on IFG connectivity at t1 and in a second step for t2 (for both F 
contrasts across all outcome measures were calculated). At t1, we found a significant effect in 
the left amygdala expanding in the temporal pole and hippocampus (Montreal Neurological 
Institute [MNI] xyz [–28,4,–24]; F = 6.28, p < .001, 3504 mm3). Contrast estimates indicated 
that this effect is predominantly driven by a positive correlation especially for PA and 
Mobility Inventory (as more panic attacks and agoraphobic symptoms a patient had at t1 as 
stronger was the connectivity between the left IFG and the left amygdala; Supplement 1). At 
t2, we found significant effects of the clinical scores in the bilateral and medial frontal 
cortices (left: MNI xyz [–32,52,26]; F = 5.10, p < .001, 6008 mm3; and MNI xyz [–32, 24, 
32]; F = 5.03, p < .001, 1448 mm3; right: MNI xyz [30,48,8]; F = 5.31, p < .001, 8872 mm3) 
as well as the anterior, middle, and posterior cingulate cortex (ACC: MNI xyz [–16,52,– 8]; F 
= 4.92, p < .001, 2176 mm3 and MNI xyz [18,50,– 6]; F = 5.10, p < .001, 1496 mm3; MCC: 
MNI xyz [– 8,30,24]; F = 4.32, p < .001, 1552 mm3); PCC: MNI xyz [–10,–52,30]; F = 5.48, 
p < .001, 2632 mm3). The negative contrast estimates at t2 for PA and MI7ac indicated a 
negative correlation between symptom severity (panic attacks and agoraphobic avoidance) 
and connectivity of the left IFG to the respective regions (Supplement 1).  
 
Discussion  
 
Panic disorder with agoraphobia is a debilitating and costly anxiety disorder (4,49) that is 
being treated effectively with CBT (7). Here, we demonstrate the effect of CBT on the neural 
networks of fear conditioning in patients with PD/A. As a main result, the interaction analyses 
demonstrated the left IFG to be involved in the pathology and successful psychotherapy of 
panic disorder (Figure 2).  
 
Evidence from research in animals and humans suggest a so-called fear network (13,15) 
including the amygdala (11,12,14,15,50), insula (12,43,51), ACC (14), and medial frontal 
brain regions (11) to be involved in fear conditioning as well as panic disorder (13,15). Even 
if not significant in the interaction analysis, we found an activation reduction in these brain 
regions after therapy in patients, indicating a significant influence of psychotherapy on brain 
pathophysiology in key areas of fear processing. By contrast, in the control group, we 
obtained activation predominantly in the pre- and postcentral gyri including inferior and 
superior parts of the parietal cortex (Table 2), which might reflect a reduction of attention 
with regard to CS+ at the second time point.  
 
Whereas the amygdala and insula have been related to negative emotional responses, the 
dorsal and rostral anterior cingulate cortices and the ventromedial prefrontal cortex have been 
connected to the experience and regulation of emotions (16,52). Regarding the insular cortex, 
a functional gradient from the posterior to the anterior insula has been described (53). It has 
been argued that anxiety disorders are predominantly reflected by altered information 
processing in the anterior insula (51,52). The amygdala plays a central role in the subjective 
feeling of fear (11,54). The pre–post comparison in our patient sample (t1 > t2) indicates a 
reduced activation of the amygdala, bilateral anterior insula, as well as parts of the dorsal and 
rostral anterior cingulate cortices and the ventromedial PFC. Thus, one might speculate that 
the reduction of activity in the amygdala and insula reflect attenuated negative emotional 
responses. The medial frontal and anterior cingulate activation may further reflect a reduced 
experience or regulation of anxiety after CBT.  
 
In contrast to these putative emotional processes related to fear network activation, the left 
IFG is involved primarily in cognitive functions (e.g., attention, execution control, reasoning, 
verbalization). Especially for panic disorder and its treatment, cognitive processes are highly 
relevant, because even conditioning processes and exposure therapy have been assumed to 
involve strong cognitive components (see Hofmann [55] for a review). Thus, our data indicate 
that cognitive processes (IFG) are tightly associated with the aberrant emotional responses 
(fear network) and the pathophysiology and treatment of panic disorder. This interpretation is 
in line with studies suggesting the frontal cortex being involved in negative cognitions such as 
worries or rumination, connected to an emotional state (56). Furthermore evidence from 
instructed fear in healthy subjects suggests an involvement of the left IFG in cognitions 
related to negative affect (30). Correspondingly, there is evidence that aversive imagery in 
PD/A increases physiologic reactions such as heart beat and startle reflex (57).  
 
We found increased IFG activation before therapy that is normalized by CBT. These results 
suggest that CBT reduces negative cognitions, such as increased harm expectancy (55) or 
attention to threat (58), related to the frontal cortex, which indicate aversive contingencies and 
consecutively activate the fear network. Our connectivity analysis further supports this 
interpretation and demonstrates the increased connection of the IFG with regions of the fear 
network in PD/A, suggesting an increased association of cognitive and emotional processes 
within the patient compared to the control group. Thus, cognitive processes might trigger 
emotional responses related to fear network activity more easily in patients with PD/A than in 
control subjects. This interpretation is supported by the positive correlation of the left IFG 
connectivity with the clinical outcome measures, which indicates that patients with higher 
rates of panic attacks and agoraphobic symptoms (MI7) had also a stronger connectivity 
between the left IFG and the left amygdala at t1.  
 
Despite the significant reduction of IFG activity after CBT, there was no change in functional 
connectivity across time in both groups. Thus, changes of connectivity might be more difficult 
to obtain or will be established only after a longer period. An alternative explanation would be 
that an increased coupling between the left IFG and regions of the fear network might 
represent a specific vulnerability (“trait”) for PD/A, but this needs to be confirmed by further 
longitudinal studies.  
 
Consistent with the two resting state positron emission tomography studies that have 
examined the modulation of brain physiology with CBT in PD (24,25), we could demonstrate 
an effect of CBT on neural mechanisms in PD/A. However, results are quite heterogeneous 
(as noted earlier), probably because of differences in the imaging method (positron emission 
tomography vs. fMRI), in sample size—n = 6 (25), n = 12 (24), n = 42 our study—and 
especially different paradigms (resting state vs. fear conditioning).  
 
However, effects of CBT on activity in regions of the fear network have been also 
demonstrated in other disorders such as schizophrenia (59) and depression (60). For example, 
in line with our results, effects of CBT on the IFG, insula, thalamus, putamen, and occipital 
areas had been shown (59). Intriguingly Fu and colleagues could show a significant positive 
association between clinical outcome and linear load-response activity (increasingly sad 
faces) in the left IFG (Brodmann’s area 44), as depressed patients with the largest clinical 
response showed the highest linear load-response in this region at baseline (60). Although 
CBT treatment protocols and disorders of these studies are different, these findings support 
the role of the (left) IFG in CBT. In line with the interpretation of Kumari et al. (59), our data 
suggest that CBT may mediate symptom reduction by promoting processing of threats in a 
less distressing way.  
 
Our findings should be interpreted within the methodologic limitations of this study. First, 
there is no group of patients receiving a control intervention. Therefore, our effects might not 
necessarily be specific to CBT and could potentially also be induced by other 
psychotherapeutic methods (61,62), pharmacotherapy (25) or spontaneous remission. Thus, 
future studies are needed to shed further light on the effects of different (psychotherapeutic) 
treatments on brain processes. Second, comorbid depression was not excluded per se because 
its presence conforms to the usual picture seen in practice and may thus improve external 
validity of the sample. However, in our fMRI analyses, we controlled for depression scores 
(Beck Depression Inventory-II), which also improved in light of CBT (63). Finally, to 
disentangle bottom up from top-down processes relevant in PD/A and exposure-based CBT, 
the inclusion of cognitive regulation tasks could be helpful in future investigations.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This study provides evidence about the link between the cerebral correlates of cognitive and 
emotional processing in interaction with CBT in patients with panic disorder. On the basis of 
these findings, we are confident that further research in this line has promising potential to 
support the development and further optimization of targeted treatments.  
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